Nutrition and dementia: Are we asking the right questions?

Journal of Alzheimer's Disease

Volumn 30, Issue 1, 2012, Pages 27-33

  Shea, Thomas B ^a   Rogers, Eugene ^a   Remington, Ruth ^a  

^a University of Massachusetts Lowell   (United States)

Author keywords

Alzheimer's disease; cognition; dementia; nutrition; pharmacology; supplement; vitamin

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CYANOCOBALAMIN; FOLIC ACID; LEVACECARNINE; OMEGA 3 FATTY ACID; PRESENILIN 1; RETINOL; S ADENOSYLMETHIONINE; TAU PROTEIN; VITAMIN B GROUP;

AGING; ALZHEIMER DISEASE; CARBON METABOLISM; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIET SUPPLEMENTATION; HUMAN; NONHUMAN; NUTRITION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITAMIN SUPPLEMENTATION;

EID: 84861490534     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112231     Document Type: Review

References (63)

1. Wollen KA (2010) Alzheimer's disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Alt Med Rev 15, 226-244.
2. Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P (2011) Pharmacologists and Alzheimer disease therapy: To boldly go where no scientist has gone before. Expert Opin Investig Drugs 20, 1243-1261.
3. Shatenstein B, Kergoat MJ, Reid I (2007) Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. J Am Diet Assoc 107, 2091-2019.
4. Vellas B, Lauque S, Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashémi F, Cantet C, Ousset PJ, Grandjean H, REAL. FR Group (2005) Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. J Nutr Health Aging 9, 75-80. (Pubitemid 40478062)
5. Guigoz Y (2006) The Mini Nutritional Assessment (MNA) review of the literature-What does it tell us? J Nutr Health Aging 10, 466-485. (Pubitemid 46127189)
6. Soto ME, Secher M, Gillette-Guyonnet S, van Kan GA, Andrieu S, Nourhashemi F, Rolland Y, Vellas B (2011) Weight loss and rapid cognitive decline in community-dwelling patients with Alzheimer's disease. J Alzheimers Dis 28, 647-654.
7. Sebastian RS, Cleveland LE, Goldman JD, Moshfegh AJ (2007) Older adults who use vitamin/mineral supplements differ from nonusers in nutrient intake adequacy and dietary attitudes. J Am Diet Assoc 107, 1322-1332. (Pubitemid 47101762)
8. de Sousa OL, Amaral TF (2011) Three-week nutritional supplementation effect on long-term nutritional status of patients with mild Alzheimer disease. Alzheimer Dis Assoc Disord, doi: 10.1097/WAD.0b013e31822c5bb3.
9. Morris MC (2011) Nutritional determinantsofcognitiveaging and dementia. Proc Nutr Soc 9, 1-13.
10. Morris MC, Tangney CC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA 305, 1348-1349.
11. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 369, 208-216. (Pubitemid 46107683)
12. Kang JH, Cook N, Manson J, Buring JE, Grodstein F (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166, 2462-2468. (Pubitemid 44913230)
13. Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grod-stein F (2008) A trial of Bvitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr 88, 1602-1610.
14. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P (2011) Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: Ancillary findings from the SU. FOL. OM3 randomized trial. Am J Clin Nutr 94, 278-286.
15. Zawia NH, Lahiri DK, Cardozo-Pelaez (2009) Epigenetics, oxidative stress and Alzheimer's disease. Free Radic Biol Med 46, 1241-1249.
16. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, Perry G (2004) Oxidative stress signaling in Alzheimer's disease. Brain Res 1000, 32-39. (Pubitemid 38446487)
17. Resende R, Moreira PI, Proença T, Deshpande A, Busciglio J, Pereira C, Oliveira CR (2008) Brain oxidative stressinatriple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44, 2051-2057.
18. Ho PI, Ortiz D, Rogers E, Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70, 694-702. (Pubitemid 35397143)
19. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22, 1752-1762. (Pubitemid 35386293)
20. Ekinci FJ, Malik KM, Shea TB (1999) fj-amyloid induces calcium influx and neurodegeneration by MAP kinase-mediated activation of the L voltage-sensitive calcium channel. J Biol Chem 274, 30322-30327.
21. Peters I, Igbavboa U, Schütt T, Haidari S, Hartig U, Rosello X, Bottner S, Copanaki E, Deller T, Kogel D, Wood WG, Müller WE, Eckert GP (2009) The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta 1788, 964-972.
22. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M (2008) Oxidative stress activates a positive feedback between the gamma-and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104, 683-695.
23. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: A chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152, 871-877. (Pubitemid 28173347)
24. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Sied-lak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215. (Pubitemid 28207848)
25. Kamboh MI (2004) Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 68, 381-404. (Pubitemid 39162750)
26. Shea TB, Rogers E (2002) Folate quenches oxidative damage in brains of apolipoprotein E-deficient mice: Augmentation by vitamin E. Mol Brain Res 108, 1-6. (Pubitemid 35447959)
27. Chan A, Tchantchou F, Graves V, Rozen R, Shea TB (2008) Dietary and genetic compromise in folate availability reduces acetylcholine and cognitive performance: Critical role of S-adenosylmethionine. J Health Nutr Aging 12, 252-261. (Pubitemid 352025873)
28. Bayer TA, Schafer S, Breyhan H, Wirths O, Treiber C, Multhaup G (2006) A vicious circle: Role of oxidative stress, intraneuronal Abeta and Cu in Alzheimer's disease. Clin Neu-ropathol 25, 163-171. (Pubitemid 44047901)
29. Mattson MM, Shea TB (2003) Folate and homocysteine in neural plasticity and neurodegenerative disorders. Trends Neurosci 26, 137-146. (Pubitemid 36183675)
30. Tchantchou F, Graves M, Falcone D, Shea TB (2008) S-adenosylmethionine mediates glutathione efficacy by increasing glutathione s-transferase activity: Implications for S-adenosyl methionine as a neuroprotective dietary supplement. J Alzheimers Dis 14, 323-328. (Pubitemid 352040043)
31. Kennedy BP, Bottiglieri T, Arning E, Zeigler MG, Hansen LA, Masliah E (2004) Elevated S-adenosylhomocysteine in Alzheimer brain: Influence on methyltransferases and cognitive function. JNeur Trans 111, 547-567. (Pubitemid 38478922)
32. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH (1990) Cerebrospinal fluid S-adenosyl-methionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53, 1096-1098.
33. Müller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W (2001) Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 308, 54-56. (Pubitemid 32607679)
34. Chan A, Tchantchou F, Rogers EJ, Shea TB (2009) Dietary deficiency increases presenilin expression, gamma-secretase activity, and Abeta levels: Potentiation by ApoE genotype and alleviation by S-adenosyl methionine. J Neurochem 110, 831-836.
35. Shea TB, Chan A (2008) S-adenosyl methionine: A natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. J Alzheimers Dis 13, 67-70. (Pubitemid 351365628)
36. Fuso A, Cavallaro RA, Zampelli A, D'Anselmi F, Piscopo P, Confaloni A, Scarpa S (2007) gamma-Secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells. J Alzheimers Dis 11, 275-290. (Pubitemid 47094027)
37. Lee S, Lemere CA, Frost JL, Shea TB (2011) Dietary supplementation with s-adenosyl methionine delayed amyloid-fj and tau pathology in 3xTg-AD mice. J Alzheimers Dis 28, 423-431.
38. Dhitavat S, Ortiz D, Rogers E, Rivera E, Shea TB (2005) Folate, vitamin E and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid beta. Brain Res 1061, 114-117. (Pubitemid 41587919)
39. Kifle K, Ortiz D, Shea TB (2009) Folate and B12 provide superior neuroprotection in combination than does either vitamin alone. J Alzheimers Dis 16, 533-540.
40. Tchantchou F, Graves M, Ortiz D, Rogers E, Shea TB (2004) Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: Relevance to age-related neurodegener-ation. Neuromolecular Med 6, 93-103. (Pubitemid 41265779)
41. Tchantchou F, Graves M, Ortiz D, Shea TB (2005) Expression and activity of methionine cycle genes are altered following folate and vitamin E deficiency under oxidative challenge: Modulation by apolipoprotein E-deficiency. Nutr Neurosci 9, 17-24. (Pubitemid 44057027)
42. Chan A, Lepore A, Kotoya E, Zemianek J, Remington R, Shea TB (2010) Efficacy of a vitamin/nutriceutical formulation on cognitive speed and recall in adults with no known or suspected dementia. J Nutr Health Aging 14, 224-230.
43. Chan A, Paskavitz J, Remington R, Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: A one-year open-label pilot study with a 16-month extension. Am J Alz Dis Other Dementias 23, 571-585.
44. Remington R, Chan A, Shea TB (2009) Efficacy of a vitamin/nutriceutical formulation for moderate to late-stage Alzheimer's disease: A placebo-controlled pilot study. Am J Alz Dis Other Dement 24, 27-33.
45. Remington R, Chan A, Lepore A, Kotlya E, Shea TB (2010) Apple juice improved behavioral symptoms in moderate-to late-stage Alzheimer's disease in an open-label pilot study. Am J Alz Dis Other Dement 25, 367-371.
46. Connelly PJ, Prentice NP, Cousland G, Bonham J (2008) A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 23, 155-160. (Pubitemid 351308495)
47. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC (2007) Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: A 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther 29, 2204-2214. (Pubitemid 350138567)
48. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388. (Pubitemid 40958434)
49. Cornelli U (2010) Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neu-rodegener Dis 7, 193-202.
50. Ballard C, Khan Z, Clack H, Corbett A (2011) Nonpharma-cological treatment of Alzheimer disease. Can J Psychiatry 56, 589-595.
51. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, Connolly ES Jr, Dunbar-Jacob JM, Granieri EC, McGarry K, Patel D, Trevisan M, Williams JW Jr (2011) Risk factors and preventive interventions for Alzheimer disease: State of the science. Arch Neurol 68, 1185-1190.
52. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A (2011) Diet and Alzheimer's disease risk factors or prevention: The current evidence. Expert Rev Neurother 11, 677-708.
53. Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D'Onofrio G, Addante F, Sancarlo D, Cascavilla L, Pilotto A, Panza F (2011) Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res 8, 520-542.
54. Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czer-niawski JL, Aliev G (2005) Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am J Alzheimers Dis Other Dement 20, 21-26. (Pubitemid 40224057)
55. Rivière S, Gillette-Guyonnet S, Voisin T, Reynish E, Andrieu S, Lauque S, Salva A, Frisoni G, Nourhashemi F, Micas M, Vellas B (2001) A nutritional education program could prevent weight loss and slow cognitive decline in Alzheimer's disease. J Nutr Health Aging 5, 295-299. (Pubitemid 33700339)
56. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer's disease. J Neurosci 24, 2401-2411. (Pubitemid 38327953)
57. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer's disease: Shared pathology and treatment?. Br J Clin Pharmacol 71, 365-376.
58. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-likegrowthfactor expressionand signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80. (Pubitemid 40387185)
59. Kroner Z (2009) The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 14, 373-379.
60. LaMonte MJ, Blair SN, Church TS (2005) Physical activity and diabetes prevention. J Appl Physiol 99, 1205-1213. (Pubitemid 41214541)
61. Qi L, Hu FB, Hu G (2008) Genes, environment, and interactions in prevention of type 2 diabetes: A focus on physical activity and lifestyle changes. Curr Mol Med 8, 519-532.
62. Okosun IS, Davis-Smith M, Seale JP (2012) Awareness of diabetes risks is associated with healthy lifestyle behavior in diabetes free American adults: Evidence from a nationally representative sample. Prim Care Diabetes, doi: 10.1016/j.pcd.2011.12.005.
63. Emery VO (2011) Alzheimer disease: Are we intervening too late? Pro. J Neural Transm 118, 1361-1378.